Antipruritic Market By Product Type (Topical Corticosteroids, Counterirritants, Antihistamines, Immunomodulators, and Others), By Route of Administration (Topical, Oral, and Parenteral), By Application (Dermatitis, Insect Bites, Allergic Reactions, and Others), By Distribution Channel (Pharmacies, Supermarkets/Hypermarkets, Online Stores, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Global Antipruritic Market size is expected to be worth around US$ 4.5 Billion by 2033, from US$ 2.6 Billion in 2023, growing at a CAGR of 5.6% during the forecast period from 2024 to 2033. North America dominated the market with a share exceeding 39.1% and a market value of USD 1 billion.

Increasing prevalence of skin conditions and rising demand for effective treatments are driving the growth of the antipruritic market. Antipruritic products, designed to relieve itching caused by conditions like eczema, acne, and psoriasis, are becoming increasingly important in both over-the-counter and prescription formulations.

The market is expanding as consumers seek fast-acting, long-lasting solutions to alleviate discomfort from chronic skin conditions. According to the National Eczema Association, over 31 million Americans suffer from some form of eczema, contributing significantly to the demand for antipruritic products.

In addition, recent data from the American Academy of Dermatology Association (AADA) indicates that approximately 50 million people in the US experience acne annually, further driving the need for effective skin care solutions. A growing aging population also fuels market growth, as individuals over 65, a group numbering approximately 52 million in the US, are more susceptible to age-related skin issues and itching.

These trends open up numerous opportunities for innovation, particularly in products targeting specific conditions like atopic dermatitis, contact dermatitis, and chronic dry skin. Recent advancements in biologic therapies and topical treatments have spurred interest in more targeted and personalized antipruritic solutions.

Moreover, consumers increasingly demand natural, clean-label products with fewer side effects, encouraging manufacturers to explore plant-based and dermatologically tested alternatives. This growing shift toward holistic and safe solutions represents a key opportunity for companies in the antipruritic market.

Key Takeaways

• In 2023, the market for Antipruritic generated a revenue of US$ 2.6 billion, with a CAGR of 5.6%, and is expected to reach US$ 4.5 billion by the year 2033.
• The product type segment is divided into topical corticosteroids, counterirritants, antihistamines, immunomodulators, and others, with topical corticosteroids taking the lead in 2023 with a market share of 37.5%.
• Considering topical corticosteroids, counterirritants, antihistamines, immunomodulators, and others, the market is divided into topical, oral, and parenteral. Among these, topicalheld a significant share of 52.6%.
• Furthermore, concerning the application segment, the market is segregated into dermatitis, insect bites, allergic reactions, and others. The dermatitissector stands out as the dominant player, holding the largest revenue share of 42.7% in the Antipruritic market.
• The distribution channel segment is segregated into pharmacies, supermarkets/hypermarkets, online stores, and others, with the pharmaciessegment leading the market, holding a revenue share of 48.3%.
• North America led the market by securing a market share of 39.1% in 2023.

Product Type Analysis

The topical corticosteroids segment led in 2023, claiming a market share of 37.5% owing to their established efficacy in treating itching and inflammation associated with various skin conditions. Corticosteroids, known for their anti-inflammatory properties, are anticipated to remain a first-line treatment for conditions such as eczema, psoriasis, and allergic reactions.

The increasing prevalence of dermatological disorders, including chronic conditions like atopic dermatitis, is likely to drive demand for topical corticosteroids. Their widespread availability in over-the-counter formulations and the relatively low cost of treatment further contribute to their market dominance.

Additionally, advancements in formulation technologies, which improve the absorption and delivery of corticosteroids, are expected to increase their therapeutic effectiveness, further fueling growth in the segment.

Route of Administration Analysis

The topicalheld a significant share of 52.6% due to the growing preference for localized treatment options. Topical formulations are likely to continue their dominance as they offer targeted relief with fewer systemic side effects compared to oral or parenteral treatments. The convenience of topical applications, such as creams, ointments, and lotions, is expected to drive adoption, particularly among patients seeking quick, easy-to-apply solutions for conditions like dermatitis or insect bites.

As consumers increasingly opt for self-care products that can be used at home, the demand for topical antipruritic solutions is projected to rise. Moreover, advancements in drug delivery systems, such as transdermal patches and enhanced penetration formulations, are anticipated to further support the growth of the topical segment in the market.

Application Analysis

The dermatitissegment had a tremendous growth rate, with a revenue share of 42.7% owing to the increasing prevalence of atopic dermatitis and other inflammatory skin conditions. The rising incidence of eczema, particularly among children and adults, is likely to contribute to the demand for effective antipruritic treatments.

As awareness of dermatitis-related itching grows, consumers are expected to seek more advanced solutions that offer rapid relief and long-term management. The rising availability of both prescription and over-the-counter products tailored for dermatitis treatment, along with improved formulations, is projected to further enhance market growth.

Additionally, the increased focus on preventive skincare and early intervention strategies is likely to support the adoption of antipruritic treatments specifically designed for dermatitis, further driving growth in this segment.

Distribution Channel Analysis

The pharmaciessegment grew at a substantial rate, generating a revenue portion of 48.3% due to their central role in providing accessible and affordable treatments for itching and skin irritations. Pharmacies, both retail and community-based, are anticipated to remain a preferred distribution channel for antipruritic products due to their wide availability and the ability to offer professional advice from pharmacists.

With an increasing number of consumers seeking quick relief from conditions like eczema, insect bites, and allergic reactions, pharmacies are expected to become more central in addressing these concerns. Furthermore, the growing preference for over-the-counter treatments, coupled with the expansion of pharmacies in emerging markets, is projected to support this segment’s growth. The accessibility of various antipruritic products, including creams, lotions, and sprays, through pharmacies is expected to drive consumer adoption and facilitate broader market penetration.

Key Market Segments

By Product Type

• Topical Corticosteroids
• Counterirritants
• Antihistamines
• Immunomodulators
• Others

By Route of Administration

• Topical
• Oral
• Parenteral

By Application

• Dermatitis
• Insect Bites
• Allergic Reactions
• Others

By Distribution Channel

• Pharmacies
• Supermarkets/Hypermarkets
• Online Stores
• Others

Drivers

Rise in Launch of New and Effective Products Driving the Market

The rise in the launch of new and effective products is driving the growth of the antipruritic market. As more innovative solutions become available, consumers are presented with a wider variety of options to address skin conditions that cause itching and discomfort. For example, in October 2022, Sonoma Pharmaceuticals, a global leader in healthcare, launched two new over-the-counter products in the United States: Rejuvacyn Advanced Skin Repair Cooling Mist and Reliefacyn Advanced Burn-Rash-Itch-Pain Relief Hydrogel.

These products, designed to treat various dermatological conditions, offer consumers effective relief for skin irritation. The introduction of such advanced products is expected to boost demand for antipruritic treatments as more consumers seek quick and convenient solutions for skin conditions.

As the market for these products grows, manufacturers are anticipated to continue developing more targeted and efficient treatments. The innovation and effectiveness of these new products are likely to fuel expansion in the antipruritic market, as they address an increasing variety of skin issues and offer promising relief.

Restraints

Adverse Side Effects Restraining the Market

Rising concerns about the adverse side effects of antipruritic treatments are expected to restrain market growth. Many consumers hesitate to use topical treatments or medications due to potential skin reactions, such as irritation, allergic responses, or other unwanted effects. These side effects could impede the widespread adoption of antipruritic products, especially for individuals with sensitive skin or those prone to adverse reactions.

The risk of overuse or misuse of certain products is likely to raise safety concerns, further hampering the market’s growth. In addition, concerns regarding long-term use and its impact on skin health may deter consumers from opting for chemical-based treatments. The growing awareness of side effects is anticipated to slow the demand for certain antipruritic products, especially if consumers perceive the risks to outweigh the benefits. Therefore, while there is a growing market for these products, the challenge of mitigating side effects is expected to remain a significant restraint.

Opportunities

Increasing Innovation and Development Creating Opportunities in the Market

Increasing innovation and development in the antipruritic market are creating significant opportunities for growth. As research advances, companies are expected to introduce more effective, targeted solutions with fewer side effects, which will likely attract a broader consumer base. For example, in May 2023, Biofrontera expanded its Belixos active cosmetic line by adding Belixos ACTIVE CARE, a soothing foam designed for irritated and itchy skin.

This product targets conditions such as topical dermatitis and psoriasis, offering relief for both minor and severe skin issues. The continued development of such products is anticipated to further drive market growth by providing more options for consumers seeking effective treatment. With advancements in both formulation and delivery methods, new products are likely to address a wider range of skin conditions, offering solutions tailored to individual needs.

The growing emphasis on innovation in the antipruritic market is projected to lead to the introduction of more effective treatments, enhancing patient satisfaction and expanding the market. As these innovations continue, companies will likely strengthen their positions in the competitive landscape, further propelling market expansion.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors play a pivotal role in shaping the antipruritic market. Economic recessions often result in tighter healthcare budgets, potentially limiting access to advanced treatments for conditions like eczema and other skin disorders. During times of economic growth, however, increased disposable income and higher healthcare spending tend to drive demand for effective antipruritic solutions.

Geopolitical factors, such as trade tensions or changes in healthcare policies, may disrupt the supply of key ingredients or treatment options, leading to fluctuations in market availability. On the positive side, increasing awareness of dermatological conditions and the growing prevalence of skin disorders worldwide bolster market demand.

Additionally, advancements in pharmaceutical research and the rising focus on improving patient care continue to provide opportunities for growth. Overall, while challenges exist, the market is likely to see positive trends moving forward, supported by both economic recovery and innovation in treatment options.

Trends

Rising Approval of Novel Treatments Driving the Antipruritic Market

Rising approval of novel treatments is significantly driving the growth of the antipruritic market. The increasing focus on advancing therapies for chronic skin conditions has led to the approval of new drugs that offer more effective solutions for patients. Regulatory bodies are granting approvals for innovative treatments, creating a surge in market activity.

For instance, Pfizer’s CIBINQO (abrocitinib) received approval from the US FDA in January 2022 for the treatment of moderate-to-severe atopic dermatitis. This approval marks a breakthrough in managing challenging cases of severe eczema, offering new hope for patients who previously had limited options.

As the approval of new treatments continues to grow, the market is expected to expand, providing more options for individuals suffering from skin conditions. With continuous advancements in medical research, the future looks promising for the antipruritic market.

Regional Analysis

North America is leading the Antipruritic Market

North America dominated the market with the highest revenue share of 39.1% owing to the increasing prevalence of skin conditions that lead to pruritus, such as eczema, psoriasis, and other dermatological disorders. According to a June 2021 report by the American Academy of Dermatology Association (AADA), approximately 85 million Americans are affected by skin diseases annually, many of which are associated with intense itching and discomfort.

The rising awareness of the impact of pruritus on quality of life has led to a growing demand for effective antipruritic treatments, particularly topical therapies and oral medications. Additionally, the expanding availability of advanced treatments, including prescription medications and over-the-counter products, has fueled market growth.

The development of novel therapies, such as biologics for severe cases of eczema and psoriasis, has provided patients with more targeted options for managing pruritus. Moreover, increasing healthcare spending and improved access to dermatological care have made these treatments more accessible, further contributing to the market’s expansion in North America.

The Asia Pacific region is expected to experience the highest CAGR during the forecast period

Asia Pacific is expected to grow with the fastest CAGR owing to rising incidences of skin disorders and an increasing focus on improving healthcare infrastructure. Skin conditions, such as eczema and atopic dermatitis, are becoming more prevalent in countries like Japan, China, and India, where changing environmental factors and urbanization contribute to rising cases.

For example, in June 2022, Otsuka Pharmaceutical Co., Ltd. launched Moizerto Ointment in Japan, a new topical treatment for atopic dermatitis. The ointment is available in two formulations, with 1 percent and 0.3 percent difamilast, offering targeted relief for individuals suffering from this chronic condition. The introduction of such treatments highlights the growing demand for more effective antipruritic options across the region.

Furthermore, the increasing adoption of advanced dermatological treatments, coupled with growing awareness of pruritus management, is anticipated to drive market expansion. As disposable income rises and healthcare access improves, the antipruritic market is projected to grow, particularly in emerging markets where chronic skin conditions are on the rise.

Key Regions and Countries

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

The major players in the Antipruritic market are actively engaged in the development and introduction of innovative products, as well as implementing strategic initiatives aimed at enhancing their competitive positioning. Key players in the antipruritic market focus on strategies such as product innovation, strategic partnerships, and expanding their global footprint to drive growth.

Companies work on enhancing the efficacy and safety profiles of topical and oral treatments to address a wide range of pruritus-related conditions. Expanding product offerings to include natural and over-the-counter options helps cater to the growing consumer demand for accessible and safe treatments. Collaborations with dermatologists and healthcare providers facilitate greater product acceptance and distribution.

Moreover, increasing investments in research and development (R&D) enable the development of next-generation therapies targeting underlying causes of itching. One of the key players in the market is GlaxoSmithKline (GSK), a leading global healthcare company. GSK’s portfolio includes several treatments for pruritus, focusing on both prescription medications and consumer health products.

The company’s growth strategy involves advancing its product range through innovation, targeting emerging markets with high unmet medical needs, and reinforcing its position through strategic alliances with healthcare professionals and institutions. GSK prioritizes scientific research to expand its treatment offerings and ensure effective solutions for patients worldwide.

Top Key Players in the Antipruritic Market

• XBiotech Inc.
• Pfizer Inc.
• NeRRe Therapeutics
• Menlo Therapeutics
• Ipsen Pharma
• Enteris BioPharma
• Cara Therapeutics
• Amorepacific

Recent Developments

• In March 2023: Ipsen completed the acquisition of Albireo Pharma, Inc., a leader in the development of bile-acid modulators for treating pediatric and adult cholestatic liver diseases. This acquisition strengthens Ipsen’s rare disease portfolio, enhancing its infrastructure and scientific capabilities to support the treatment of these challenging conditions.
• In March 2023: the US FDA accepted a supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) to treat chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 and older. This indication, targeting patients with CSU not adequately controlled by H1 antihistamine treatment, is expected to be decided by the FDA on October 22, 2023.
• In May 2021: Pfizer introduced Xyzal Allergy 24HR, an antihistamine used to treat a range of allergic conditions, including pruritus caused by allergic reactions. This new product adds to Pfizer’s portfolio of treatments for allergic conditions and offers a convenient, once-daily solution for managing symptoms.

Report Scope